Product Description
Mechanisms of Action: PLA Activator
Novel Mechanism: No
Modality: N/A
Route of Administration: Intravenous,Percutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Bangladesh | Brazil | Bulgaria | Canada | Chile | Colombia | Denmark | Dominican Republic | Ecuador | Egypt | Germany | Greece | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Malaysia | Malta | Mexico | Morocco | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Russia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Taiwan | Thailand | Ukraine | United Kingdom | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|